{
    "clinical_study": {
        "@rank": "168329", 
        "acronym": "ONC006", 
        "biospec_descr": {
            "textblock": "Remaininig lung tissue after resection and confirmed diagnosis."
        }, 
        "biospec_retention": "Samples Without DNA", 
        "brief_summary": {
            "textblock": "This registry is intended to measure the effect of myPlan Lung Cancer\u2122 test has on\n      influencing treatment decisions of Oncologists when added to standard clinical-pathological\n      parameters in patients with early stage NSCLC.\n\n      The sponsor is conducting two parallel registries, with one directed at Surgeons (ONC003)\n      and the other at Oncologists (ONC006). This registry is specific to Oncologists (ONC006)."
        }, 
        "brief_title": "Registry Measuring the Impact of Adding RNA Expression Testing on Referral Decisions Early Stage Lung Cancer Patients (ONC006_Oncologist Specific)", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Lung Cancer", 
            "NSCLC", 
            "NSCLC Adenocarcinoma"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Adenocarcinoma", 
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis of early stage non-small cell lung adenocarcinoma\n\n          -  Sub-population staging (IA, IB or IIA) as judged by the standard of practice at the\n             investigational site\n\n          -  Resection of tumor within previous 2 months of enrollment\n\n          -  ECOG performance of 0-2\n\n          -  A minimum life expectancy of six months\n\n        Exclusion Criteria\n\n          -  Previous myPlan Lung Cancer test performed\n\n          -  Pre-operative radiation or chemotherapy for NSCLC\n\n          -  Post-operative radiation or chemotherapy for NSCLC\n\n          -  Enrollment in a separate clinical trial restricting treatment options\n\n          -  Unable to provide informed consent"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Recently diagnosed treatment-na\u00efve patients with early stage NSCLC (lung adenocarcinoma)"
            }
        }, 
        "enrollment": {
            "#text": "250", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 22, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02121899", 
            "org_study_id": "myPlan ONC006"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Registry", 
        "lastchanged_date": "May 5, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Salt Lake City", 
                    "country": "United States", 
                    "state": "Utah", 
                    "zip": "84108"
                }
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "1", 
        "official_title": "LUNG CAncerREgistry: An Open Registry to Measure the Impact of Adding RNA Expression Testing (myPlan Lung Cancer) on Referral Decisions in Newly Diagnosed Early Stage Lung Adenocarcinoma Patients (LUNG CARE Registry)", 
        "overall_contact": {
            "email": "krushton@myriad.com", 
            "last_name": "Kristen Rushton"
        }, 
        "overall_official": {
            "affiliation": "Myriad Genetic Laboratories, Inc.", 
            "last_name": "Abebe Haregewoin, MD., Ph.D", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "August 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Percentage change from the recorded PRE-TEST treatment recommendation by the oncologist versus the POST-TEST treatment initiated.", 
            "safety_issue": "No", 
            "time_frame": "3 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02121899"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Myriad Genetic Laboratories, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Myriad Genetic Laboratories, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational [Patient Registry]", 
        "target_duration": "90 Days", 
        "verification_date": "May 2014"
    }
}